Nuvalent, Inc.
NUVL evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $9.79B
- Cash Runway:
- 40.2 mo
What it means
What to watch
Prepared research question
What matters most for NUVL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing precisely targeted kinase inhibitors for cancer, with lead candidates zidesamtinib (ROS1) and neladalkib (ALK) under FDA review and a cash runway extending into 2029.
Key risk: Regulatory approval uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 6 clinical trials · 1 catalyst · 1 FDA decision for Nuvalent, Inc..
Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing precisely targeted kinase inhibitors for cancer, with lead candidates zidesamtinib (ROS1) and neladalkib (ALK) under FDA review and a cash runway extending into 2029.
- Nuvalent has no approved products and has not generated product revenue; net loss was $109.3M for the three months ended March 31, 2026 [sec].
- Cash and equivalents were $159.7M as of March 31, 2026, with shareholders' equity of $1,174.4M [sec].
- NDA for zidesamtinib in TKI pre-treated ROS1-positive NSCLC was accepted by FDA with a PDUFA target action date of September 18, 2026 [sec · filed 2026-04-28].
- NDA for neladalkib in TKI pre-treated ALK-positive NSCLC was submitted to FDA in April 2026 [sec · filed 2026-04-28].
- A $500M public offering completed in 2025 is expected to extend cash runway into 2029, exclusive of potential product revenues [sec · filed 2026-04-28].
What works
- Two lead candidates (zidesamtinib and neladalkib) have NDAs under FDA review, targeting defined unmet needs in ROS1- and ALK-positive NSCLC [sec · filed 2026-04-28].
- Preclinical data for NVL-330 (HER2-altered NSCLC) showed favorable brain partitioning and intracranial regression in models, including after progression on zongertinib [sec_mda · as of 2026-05-07].
- The company completed a $500M public offering in 2025, extending cash runway into 2029 and providing financial flexibility for development and potential launch [sec · filed 2026-04-28].
What to weigh
- Nuvalent has no approved products and has never generated product revenue; it remains dependent on successful development and regulatory approval of its candidates [sec_mda · as of 2026-05-07].
- The company reported a net loss of $109.3M for the three months ended March 31, 2026, reflecting high R&D and administrative costs [sec_mda · as of 2026-05-07].
- All pipeline candidates are in clinical or preclinical stages, with no guarantee of successful registration or commercial adoption [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Zidesamtinib NDA accepted with PDUFA date of September 18, 2026
“assigned a Prescription Drug User Fee Act target action date of September 18, 2026”
SEC MD&A · April 28, 2026
Neladalkib NDA submitted to FDA in April 2026
“announced the submission of our NDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC to the FDA”
SEC filings · April 28, 2026
Net loss of $109.3M for Q1 2026
“We reported net losses of $109.3 million for the three months ended March 31, 2026”
SEC MD&A · May 7, 2026
Cash runway extended into 2029 via $500M offering
“completion of our successful $500 million public offering of our Class A common stock, which is expected to extend our cash runway into 2029”
SEC filings · April 28, 2026
Catalyst timeline
- 2042-09-30 · Patent_Expiry · ZIDESAMTINIB — Patent_Expiry: NDA220185 — Patent expiry for zidesamtinib; this is a long-term event with no near-term impact on stock.
Risks & what to watch (4)›
Key risks
- Regulatory approval uncertainty — Both NDAs are under FDA review; any delays or rejections would materially impact the company's prospects [sec · filed 2026-04-28].
- No product revenue history — Nuvalent has never generated product revenue and relies on external capital to fund operations [sec_mda · as of 2026-05-07].
- Clinical trial execution risk — Ongoing trials (ARROS-1, ALKOVE-1, HEROEX-1) may fail to meet endpoints or enroll adequately [sec_mda · as of 2026-05-07].
- Competitive landscape — Multiple approved and investigational TKIs exist for ROS1, ALK, and HER2-altered NSCLC, potentially limiting market share [sec_mda · as of 2026-05-07].
What to watch
- PDUFA decision for zidesamtinib on September 18, 2026 [sec · filed 2026-04-28].
- FDA action on neladalkib NDA, submitted April 2026 [sec · filed 2026-04-28].
- Data submission for zidesamtinib in TKI-naïve patients in H2 2026 [sec · filed 2026-04-28].
- Enrollment and interim data from ALKAZAR Phase 3 trial of neladalkib [sec · filed 2026-04-28].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Nuvalent, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nuvalent, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
40.2 months
D/E 0.13 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~5830d
0 buys · 39 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
263
Total value held
$7.92B
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 17,248,450 | $1.77B |
| fmr llc | 9,274,959 | $950.2M |
| paradigm biocapital advisors lp | 5,324,433 | $545.5M |
| blackrock, inc. | 4,824,785 | $494.3M |
| jpmorgan chase & co | 3,088,349 | $298.7M |
| ra capital management, l.p. | 2,534,145 | $259.6M |
| vanguard portfolio management llc | 2,500,907 | $256.2M |
| wellington management group llp | 2,470,491 | $253.1M |
| vanguard capital management llc | 2,428,488 | $248.8M |
| state street corp | 2,035,831 | $208.6M |
Showing top 10 of 263 institutional holders of Nuvalent, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 12.2%
- Days to cover
- 7.7
- Shares short
- 4,586,581
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NUVL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nuvalent, Inc.?
Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing precisely targeted kinase inhibitors for cancer, with lead candidates zidesamtinib (ROS1) and neladalkib (ALK) under FDA review and a cash runway extending into 2029.
What is Nuvalent, Inc.'s next catalyst?
Nuvalent, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA220185" — expected September 30, 2042.
Who is the CEO of Nuvalent, Inc.?
Dr. James R. Porter Ph.D. is the chief executive officer of Nuvalent, Inc. (NUVL).
Where is Nuvalent, Inc. headquartered?
Nuvalent, Inc. (NUVL) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Nuvalent, Inc. focus on?
Nuvalent, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.